Liposomes (LP) deliver drug to tumors due to enhanced permeability and retention (EPR). LP were labeled with Cu for positron emission tomography (PET) to image tumor localization. Bevacizumab (bev), a VEGF targeted antibody, may modify LP delivery by altering tumor EPR and this change can also be imaged.
View Article and Find Full Text PDF